Minor
DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Primary completion date changed from estimate of Jun 2026 to Aug 12, 2026
DualityBio Inc.Phase 3 NCT06018337 Registry history of NCT06018337 on ClinicalTrials.gov (opens the registry)